Drug intelligence / Profile preview

sars-cov-2 vaccine inactivated vero cell

Development stage
Phase 3
Lead developer
Sinovac Biotech
Modality
Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

SARS-CoV-2 vaccine inactivated, Vero cell is an inactivated whole-virus COVID-19 vaccine produced using the Vero cell line derived from African green monkey kidney cells. The virus (typically CZ02 or 19nCoV-CDC-Tan-HB02 strain) is cultured on Vero cells, harvested, and then chemically inactivated (commonly with β-propiolactone). The resulting viral particles are purified and adsorbed onto aluminum hydroxide as an adjuvant. This formulation stimulates the immune system to produce neutralizing antibodies against SARS-CoV-2 without causing disease. It is indicated for active immunization to prevent COVID-19 and has been widely used globally under various brand names such as CoronaVac (Sinovac) and Covilo (Sinopharm). The primary indication is prevention of COVID-19 infection[1][2][3].

Brand names
CoronaVac
Other names
covid-19 vaccine vero cell inactivatedcovid19 vaccine vero cell inactivatedcovid 19 vaccine vero cell inactivatedcoviloxinxing guanzhuang bingdu miehuoyimiao vero xibao

Beyond the preview

Go deeper on sars-cov-2 vaccine inactivated vero cell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sars-cov-2 vaccine inactivated vero cell.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call